Welcome to our dedicated page for Starling Oncology SEC filings (Ticker: DFPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Starling Oncology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Starling Oncology's regulatory disclosures and financial reporting.
Pacala Mark L reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Mark L. Pacala received an equity award of 30,120 restricted stock units (RSUs), each settling into one share of common stock. The RSUs vest in full at the company’s 2027 annual meeting of stockholders, subject to his continued service, bringing his direct holdings to 286,881 shares.
STOLPER MARK reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Mark Stolper reported an equity compensation grant of 31,124 shares of Common Stock in the form of restricted stock units (RSUs) on 2026-07-27. Each RSU entitles him to receive one share of common stock upon settlement and vests in full on the date of the company’s 2027 annual meeting of stockholders, contingent on his continued service through that date. Following this award, Stolper directly holds 56,957 shares of common stock. The RSUs were granted at a stated price of $0.00 per share, reflecting their nature as a compensation grant rather than a market purchase.
TZOUMAKAS KIMBERLY JO reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director TZOUMAKAS KIMBERLY JO received a grant of 29,116 restricted stock units on July 27, 2026, each entitling her to one share of common stock upon settlement. These RSUs vest in full at the 2027 annual meeting of stockholders, bringing her direct holdings to 46,301 shares.
Hively Brad reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that director Brad Hively received an equity grant of 27,108 shares of common stock on July 27, 2026, structured as restricted stock units (RSUs) at a stated price of $0.0000 per share. Each RSU entitles him to one share of common stock upon settlement and vests in full on the date of the company’s 2027 annual meeting of stockholders, subject to his continued service with the company through that date. Following this award, Hively directly holds 710,829 shares of Oncology Institute common stock.
Johnson Karen Marie reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. granted director Karen Marie Johnson 31,124 restricted stock units (RSUs), each convertible into one share of common stock. The RSUs vest in full at the company’s 2027 annual meeting of stockholders, subject to her continued service, increasing her direct holdings to 319,410 shares.
Oncology Institute, Inc. ten percent owner Jorey Chernett purchased 18,000 shares of Common Stock on July 21, 2026 at a weighted average price of $5.27 per share in open-market or private transactions. Following this transaction, Chernett directly owns 10,648,858 shares of Oncology Institute common stock. The reported price reflects multiple trades between $5.27 and $5.28 per share, based on the weighted-average pricing disclosure.
Oncology Institute, Inc. Chief Medical Officer Yale Podnos reported an option exercise-and-sale sequence on July 14, 2026. He exercised stock options for a total of 23,452 common shares at strike prices of $2.00 and $1.87, then sold all corresponding shares in open-market trades at prices of $6.35 and $6.429. The transactions were executed under a pre-arranged Rule 10(b) 5-1 trading plan. Following these trades, he directly holds 259,527 shares of common stock.
TOI reports a Form 144 notice for the potential sale of 23,452 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an aggregate market value of $146,575.00. The shares are shown as acquired on 07/14/2026 via an Exercise of Stock Options from the issuer for cash.
The filing also lists recent Rule 10b5-1 sales by Yale D. Podnos: on 06/08/2026, 23,451 common shares for $126,093.70, and on 05/21/2026, 1,805 common shares for $8,068.35.
TZOUMAKAS KIMBERLY JO reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Kimberly Jo Tzoumakas received a fully vested restricted stock unit (RSU) award of 17,185 shares of common stock on July 7, 2026. The grant is recorded at a price of $0.00 per share as equity compensation rather than an open-market purchase, and her directly held stake after this award is 17,185 shares.
STOLPER MARK reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Mark Stolper reported an equity compensation grant of 25,833 shares of Common Stock on July 7, 2026. The Form 4 classifies this as a grant or award (code A) at a stated price of $0.00 per share, reflecting a non-cash award. A footnote explains that the grant represents an RSU award that was fully vested upon grant. Following this transaction, Stolper directly owns 25,833 shares of Oncology Institute common stock.